Stimwave Appoints Pat Tompkins as Executive Vice President of Sales

Stimwave Appoints Pat Tompkins as Executive Vice President of Sales

New Sales Team to Support Market Demand for Stimwave’s Disruptive Technologies

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, announced the appointment of Pat Tompkins as executive vice president of sales in the United States. With an extensive background in developing pioneering technology and applications, as well as efficiency-focused operations and commercialization of unique medical products, Tompkins is uniquely qualified to lead Stimwave’s US sales efforts for its Wireless Pain Relief® alternative to opioids pain management solution. Tompkins will lead an augmented sales team tasked with bringing Stimwave’s wireless pain relief system to the more than 400 million patients worldwide who suffer from chronic pain.

Tompkins has more than 20 years of experience in the medical device field and has expertise in driving market adoption of new and disruptive technologies, increasing sales and profitability through the recruitment and development of excellent talent, building KOL relationships, directing cross functional teams, and growing international business. He was most recently vice president of sales at Interrad Medical for three years. Prior to that role, Tompkins worked as vice president of sales for St. Jude Medical for eight years and at Entero Medics as executive director for a year and a half. Tompkins received his Bachelor of Science in Management from St. John’s University.

“We are thrilled to have Pat on board – he’s an expert in the field, and under his leadership Stimwave is position to continue to build a world class direct sales network to support the demand for Stimwave nationwide from chronic pain sufferers who need it the most,” said Laura Perryman, Founder and CEO of Stimwave.

Stimwave’s devices use Wireless Pain Relief® technology and are 95 percent smaller than any other neuromodulation device on the market. The device delivers small pulses of energy to specific nerves, triggering a reaction that enables the brain to remap pain pathways, thus providing pain relief.

Stimwave launched its FDA-cleared devices for the relief of chronic back and leg pain to a limited number of patients throughout 2015. In March 2016, Stimwave was granted FDA 510(k) for the relief of peripheral nervous system (PNS) pain, becoming the only neuromodulation device manufacturer cleared by the FDA to help reduce chronic neuropathic pain at most locations throughout the body, from back and leg pain addressed by spinal cord stimulation to PNS treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.


Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.


Glodow Nead Communications
Evan Nicholson, Sonia Sparks, Kati Stadum, and Sarah Rogers, 415-394-6500